NASDAQ:SNY

Sanofi Competitors

$51.30
+0.61 (+1.20 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$50.80
Now: $51.30
$51.48
50-Day Range
$45.46
MA: $48.60
$50.77
52-Week Range
$43.17
Now: $51.30
$55.00
Volume958,078 shs
Average Volume2.45 million shs
Market Capitalization$129.17 billion
P/E Ratio21.92
Dividend Yield2.33%
Beta0.55

Competitors

Sanofi (NASDAQ:SNY) Vs. JNJ, ABT, PFE, NVS, MRK, and ABBV

Should you be buying SNY stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Sanofi, including Johnson & Johnson (JNJ), Abbott Laboratories (ABT), Pfizer (PFE), Novartis (NVS), Merck & Co., Inc. (MRK), and AbbVie (ABBV).

Johnson & Johnson (NYSE:JNJ) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, dividends and profitability.

Dividends

Johnson & Johnson pays an annual dividend of $4.04 per share and has a dividend yield of 2.5%. Sanofi pays an annual dividend of $1.17 per share and has a dividend yield of 2.3%. Johnson & Johnson pays out 46.5% of its earnings in the form of a dividend. Sanofi pays out 35.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Johnson & Johnson has raised its dividend for 59 consecutive years and Sanofi has raised its dividend for 1 consecutive years. Johnson & Johnson is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Risk & Volatility

Johnson & Johnson has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500. Comparatively, Sanofi has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for Johnson & Johnson and Sanofi, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Johnson & Johnson031102.79
Sanofi14402.33

Johnson & Johnson presently has a consensus price target of $182.6154, indicating a potential upside of 12.56%. Given Johnson & Johnson's stronger consensus rating and higher possible upside, equities research analysts clearly believe Johnson & Johnson is more favorable than Sanofi.

Valuation & Earnings

This table compares Johnson & Johnson and Sanofi's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Johnson & Johnson$82.06 billion5.21$15.12 billion$8.6818.69
Sanofi$40.00 billion3.23$3.26 billion$3.3215.45

Johnson & Johnson has higher revenue and earnings than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

67.3% of Johnson & Johnson shares are held by institutional investors. Comparatively, 6.9% of Sanofi shares are held by institutional investors. 0.3% of Johnson & Johnson shares are held by insiders. Comparatively, 1.0% of Sanofi shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Johnson & Johnson and Sanofi's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Johnson & Johnson21.01%34.64%13.40%
Sanofi14.49%24.77%13.28%

Summary

Johnson & Johnson beats Sanofi on 15 of the 17 factors compared between the two stocks.

Abbott Laboratories (NYSE:ABT) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, profitability and dividends.

Dividends

Abbott Laboratories pays an annual dividend of $1.80 per share and has a dividend yield of 1.4%. Sanofi pays an annual dividend of $1.17 per share and has a dividend yield of 2.3%. Abbott Laboratories pays out 55.6% of its earnings in the form of a dividend. Sanofi pays out 35.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Abbott Laboratories has increased its dividend for 49 consecutive years and Sanofi has increased its dividend for 1 consecutive years. Sanofi is clearly the better dividend stock, given its higher yield and lower payout ratio.

Volatility & Risk

Abbott Laboratories has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500. Comparatively, Sanofi has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations for Abbott Laboratories and Sanofi, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abbott Laboratories121402.76
Sanofi14402.33

Abbott Laboratories currently has a consensus price target of $123.2222, indicating a potential downside of 0.91%. Given Abbott Laboratories' stronger consensus rating and higher possible upside, analysts plainly believe Abbott Laboratories is more favorable than Sanofi.

Valuation and Earnings

This table compares Abbott Laboratories and Sanofi's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abbott Laboratories$31.90 billion6.90$3.69 billion$3.2438.38
Sanofi$40.00 billion3.23$3.26 billion$3.3215.45

Abbott Laboratories has higher earnings, but lower revenue than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

72.6% of Abbott Laboratories shares are owned by institutional investors. Comparatively, 6.9% of Sanofi shares are owned by institutional investors. 1.7% of Abbott Laboratories shares are owned by company insiders. Comparatively, 1.0% of Sanofi shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Abbott Laboratories and Sanofi's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Abbott Laboratories10.50%18.19%8.29%
Sanofi14.49%24.77%13.28%

Summary

Abbott Laboratories beats Sanofi on 10 of the 17 factors compared between the two stocks.

Pfizer (NYSE:PFE) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, profitability and dividends.

Institutional and Insider Ownership

67.4% of Pfizer shares are owned by institutional investors. Comparatively, 6.9% of Sanofi shares are owned by institutional investors. 0.1% of Pfizer shares are owned by company insiders. Comparatively, 1.0% of Sanofi shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

Pfizer has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500. Comparatively, Sanofi has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500.

Profitability

This table compares Pfizer and Sanofi's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pfizer17.85%24.88%9.32%
Sanofi14.49%24.77%13.28%

Dividends

Pfizer pays an annual dividend of $1.56 per share and has a dividend yield of 4.0%. Sanofi pays an annual dividend of $1.17 per share and has a dividend yield of 2.3%. Pfizer pays out 52.9% of its earnings in the form of a dividend. Sanofi pays out 35.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Pfizer has increased its dividend for 1 consecutive years and Sanofi has increased its dividend for 1 consecutive years.

Valuation and Earnings

This table compares Pfizer and Sanofi's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pfizer$51.75 billion4.16$16.27 billion$2.9513.07
Sanofi$40.00 billion3.23$3.26 billion$3.3215.45

Pfizer has higher revenue and earnings than Sanofi. Pfizer is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations for Pfizer and Sanofi, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pfizer010302.23
Sanofi14402.33

Pfizer currently has a consensus price target of $38.5714, indicating a potential upside of 0.00%. Given Pfizer's higher possible upside, analysts plainly believe Pfizer is more favorable than Sanofi.

Summary

Pfizer beats Sanofi on 10 of the 16 factors compared between the two stocks.

Novartis (NYSE:NVS) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, risk, profitability and earnings.

Institutional and Insider Ownership

9.9% of Novartis shares are held by institutional investors. Comparatively, 6.9% of Sanofi shares are held by institutional investors. 0.0% of Novartis shares are held by company insiders. Comparatively, 1.0% of Sanofi shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Novartis has a beta of 0.59, indicating that its stock price is 41% less volatile than the S&P 500. Comparatively, Sanofi has a beta of 0.55, indicating that its stock price is 45% less volatile than the S&P 500.

Profitability

This table compares Novartis and Sanofi's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Novartis14.71%24.39%10.59%
Sanofi14.49%24.77%13.28%

Dividends

Novartis pays an annual dividend of $2.08 per share and has a dividend yield of 2.4%. Sanofi pays an annual dividend of $1.17 per share and has a dividend yield of 2.3%. Novartis pays out 39.7% of its earnings in the form of a dividend. Sanofi pays out 35.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Novartis has increased its dividend for 1 consecutive years and Sanofi has increased its dividend for 1 consecutive years.

Valuation & Earnings

This table compares Novartis and Sanofi's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novartis$47.50 billion4.24$11.73 billion$5.2416.80
Sanofi$40.00 billion3.23$3.26 billion$3.3215.45

Novartis has higher revenue and earnings than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings for Novartis and Sanofi, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Novartis24602.33
Sanofi14402.33

Novartis currently has a consensus price target of $108.50, indicating a potential upside of 23.27%. Given Novartis' higher possible upside, equities analysts plainly believe Novartis is more favorable than Sanofi.

Summary

Novartis beats Sanofi on 11 of the 15 factors compared between the two stocks.

Merck & Co., Inc. (NYSE:MRK) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, risk, profitability and earnings.

Institutional and Insider Ownership

72.9% of Merck & Co., Inc. shares are held by institutional investors. Comparatively, 6.9% of Sanofi shares are held by institutional investors. 0.3% of Merck & Co., Inc. shares are held by company insiders. Comparatively, 1.0% of Sanofi shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Merck & Co., Inc. has a beta of 0.43, indicating that its stock price is 57% less volatile than the S&P 500. Comparatively, Sanofi has a beta of 0.55, indicating that its stock price is 45% less volatile than the S&P 500.

Profitability

This table compares Merck & Co., Inc. and Sanofi's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Merck & Co., Inc.24.33%53.83%16.83%
Sanofi14.49%24.77%13.28%

Dividends

Merck & Co., Inc. pays an annual dividend of $2.60 per share and has a dividend yield of 3.4%. Sanofi pays an annual dividend of $1.17 per share and has a dividend yield of 2.3%. Merck & Co., Inc. pays out 50.1% of its earnings in the form of a dividend. Sanofi pays out 35.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Merck & Co., Inc. has increased its dividend for 1 consecutive years and Sanofi has increased its dividend for 1 consecutive years.

Valuation & Earnings

This table compares Merck & Co., Inc. and Sanofi's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Merck & Co., Inc.$46.84 billion4.19$9.84 billion$5.1914.93
Sanofi$40.00 billion3.23$3.26 billion$3.3215.45

Merck & Co., Inc. has higher revenue and earnings than Sanofi. Merck & Co., Inc. is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings for Merck & Co., Inc. and Sanofi, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Merck & Co., Inc.021102.85
Sanofi14402.33

Merck & Co., Inc. currently has a consensus price target of $96.2727, indicating a potential upside of 24.27%. Given Merck & Co., Inc.'s stronger consensus rating and higher possible upside, equities analysts plainly believe Merck & Co., Inc. is more favorable than Sanofi.

Summary

Merck & Co., Inc. beats Sanofi on 12 of the 16 factors compared between the two stocks.

AbbVie (NYSE:ABBV) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, risk, profitability and earnings.

Institutional and Insider Ownership

67.5% of AbbVie shares are held by institutional investors. Comparatively, 6.9% of Sanofi shares are held by institutional investors. 0.1% of AbbVie shares are held by company insiders. Comparatively, 1.0% of Sanofi shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

AbbVie has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500. Comparatively, Sanofi has a beta of 0.55, indicating that its stock price is 45% less volatile than the S&P 500.

Profitability

This table compares AbbVie and Sanofi's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AbbVie18.16%439.24%13.22%
Sanofi14.49%24.77%13.28%

Dividends

AbbVie pays an annual dividend of $5.20 per share and has a dividend yield of 4.8%. Sanofi pays an annual dividend of $1.17 per share and has a dividend yield of 2.3%. AbbVie pays out 58.2% of its earnings in the form of a dividend. Sanofi pays out 35.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. AbbVie has increased its dividend for 49 consecutive years and Sanofi has increased its dividend for 1 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Valuation & Earnings

This table compares AbbVie and Sanofi's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbbVie$33.27 billion5.72$7.88 billion$8.9412.07
Sanofi$40.00 billion3.23$3.26 billion$3.3215.45

AbbVie has higher earnings, but lower revenue than Sanofi. AbbVie is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings for AbbVie and Sanofi, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AbbVie121302.75
Sanofi14402.33

AbbVie currently has a consensus price target of $115.75, indicating a potential upside of 7.27%. Given AbbVie's stronger consensus rating and higher possible upside, equities analysts plainly believe AbbVie is more favorable than Sanofi.

Summary

AbbVie beats Sanofi on 13 of the 17 factors compared between the two stocks.


Sanofi Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Johnson & Johnson logo
JNJ
Johnson & Johnson
2.7$162.24+1.1%$427.13 billion$82.06 billion25.51Upcoming Earnings
Abbott Laboratories logo
ABT
Abbott Laboratories
2.4$124.35+0.3%$220.29 billion$31.90 billion65.79Upcoming Earnings
Analyst Report
Pfizer logo
PFE
Pfizer
2.3$38.57+2.5%$215.13 billion$51.75 billion24.88Analyst Revision
Novartis logo
NVS
Novartis
2.0$88.02+0.9%$201.45 billion$47.50 billion28.49Analyst Revision
Merck & Co., Inc. logo
MRK
Merck & Co., Inc.
2.2$77.47+1.0%$196.03 billion$46.84 billion17.14Increase in Short Interest
Analyst Revision
News Coverage
AbbVie logo
ABBV
AbbVie
2.8$107.91+0.9%$190.44 billion$33.27 billion22.81Analyst Revision
Eli Lilly and logo
LLY
Eli Lilly and
2.1$189.25+1.8%$181.49 billion$22.32 billion30.92Analyst Revision
News Coverage
Novo Nordisk A/S logo
NVO
Novo Nordisk A/S
1.4$72.17+0.9%$169.95 billion$18.30 billion27.13Analyst Revision
Bristol-Myers Squibb logo
BMY
Bristol-Myers Squibb
2.3$65.46+1.6%$146.23 billion$26.15 billion-595.04Analyst Upgrade
Decrease in Short Interest
Analyst Revision
AstraZeneca logo
AZN
AstraZeneca
2.1$50.74+0.2%$133.17 billion$24.38 billion52.85Analyst Revision
GlaxoSmithKline logo
GSK
GlaxoSmithKline
1.1$37.75+0.2%$101.65 billion$43.10 billion11.62Unusual Options Activity
Analyst Revision
News Coverage
Zoetis logo
ZTS
Zoetis
2.2$167.63+1.3%$79.62 billion$6.26 billion49.74Increase in Short Interest
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.2$219.39+0.8%$56.78 billion$4.16 billion27.70Analyst Revision
Takeda Pharmaceutical logo
TAK
Takeda Pharmaceutical
1.3$17.08+0.7%$53.90 billion$30.20 billion56.94Unusual Options Activity
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$502.60+1.6%$53.84 billion$7.86 billion18.37Analyst Report
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.7$163.68+3.8%$35.98 billion$4.99 billion38.24Unusual Options Activity
News Coverage
Gap Down
BeiGene logo
BGNE
BeiGene
1.3$305.54+0.7%$28.02 billion$428.21 million-15.12Analyst Downgrade
Royalty Pharma logo
RPRX
Royalty Pharma
1.7$41.87+0.5%$25.42 billionN/A0.00Dividend Announcement
Insider Selling
Increase in Short Interest
News Coverage
Genmab A/S logo
GMAB
Genmab A/S
1.4$35.23+0.7%$23.11 billion$804.57 million27.31Decrease in Short Interest
Analyst Revision
News Coverage
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.4$93.27+0.3%$20.90 billion$1.30 billion25.48Insider Selling
CureVac logo
CVAC
CureVac
0.6$109.29+4.8%$20.43 billionN/A0.00Analyst Downgrade
Unusual Options Activity
News Coverage
Gap Down
Catalent logo
CTLT
Catalent
1.7$110.60+0.4%$18.83 billion$3.09 billion70.45Unusual Options Activity
Analyst Revision
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$138.88+0.1%$16.29 billion$219.75 million-17.74
Zai Lab logo
ZLAB
Zai Lab
1.4$164.29+0.4%$14.55 billion$12.98 million-54.22Analyst Report
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
1.9$79.40+0.8%$14.44 billion$1.70 billion18.17News Coverage
Elanco Animal Health logo
ELAN
Elanco Animal Health
1.4$29.98+0.7%$14.17 billion$3.07 billion-52.60Analyst Report
Grifols logo
GRFS
Grifols
1.3$17.98+1.6%$12.36 billion$5.71 billion16.05Upcoming Earnings
News Coverage
Gap Up
Teva Pharmaceutical Industries logo
TEVA
Teva Pharmaceutical Industries
1.6$10.75+0.7%$11.74 billion$16.89 billion-2.92Decrease in Short Interest
News Coverage
Dr. Reddy's Laboratories logo
RDY
Dr. Reddy's Laboratories
1.3$65.01+1.4%$10.81 billion$2.32 billion53.73
Bausch Health Companies logo
BHC
Bausch Health Companies
1.7$30.03+0.9%$10.68 billion$8.60 billion-5.51
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
2.1$168.90+0.3%$9.51 billion$2.16 billion53.28Analyst Report
Maravai LifeSciences logo
MRVI
Maravai LifeSciences
1.6$36.68+0.1%$9.45 billionN/A0.00Increase in Short Interest
United Therapeutics logo
UTHR
United Therapeutics
1.5$203.73+1.0%$9.07 billion$1.45 billion19.27Analyst Report
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
2.0$55.12+0.3%$8.21 billion$40.56 million-16.16
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.6$158.19+3.7%$8.01 billion$3.34 million-20.54Unusual Options Activity
News Coverage
Gap Down
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.4$108.72+0.8%$7.28 billion$103.71 million-24.77Analyst Revision
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.5$67.65+0.5%$7.02 billion$87.99 million-80.54News Coverage
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.5$218.90+0.0%$6.86 billion$311.33 million-127.27Increase in Short Interest
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$121.95+1.8%$6.55 billion$14.98 million-14.85Analyst Downgrade
News Coverage
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$44.78+2.3%$6.30 billion$150,000.00-21.12High Trading Volume
Unusual Options Activity
News Coverage
Gap Down
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$40.78+0.6%$5.74 billion$1.12 billion84.96Analyst Revision
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$71.80+1.2%$5.70 billion$380.83 million-9.18Analyst Report
News Coverage
Perrigo logo
PRGO
Perrigo
2.3$41.62+1.1%$5.56 billion$4.84 billion-693.55
Allakos logo
ALLK
Allakos
1.7$104.50+3.5%$5.55 billionN/A-38.14Insider Selling
Gap Down
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$95.20+0.8%$5.52 billion$66.51 million17.56Analyst Report
Analyst Revision
News Coverage
Schrödinger logo
SDGR
Schrödinger
1.3$77.90+0.6%$5.45 billion$85.54 million0.00Insider Selling
News Coverage
Galapagos logo
GLPG
Galapagos
1.3$79.15+0.3%$5.19 billion$1.00 billion-11.99Analyst Upgrade
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$74.40+1.9%$4.62 billionN/A-6.06Analyst Revision
Gap Down
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$74.64+1.2%$4.36 billion$6.87 million-7.21Unusual Options Activity
Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.25+0.4%$4.26 billion$204.89 million-36.56
This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.